



● INVITED REVIEW

# Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy

Asha Hiremathad<sup>1</sup>, Luca Piemontese<sup>2,\*</sup>

1 Centre for Nano and Material Sciences, Jain University, Jain Global Campus, Kanakapura, Ramanagaram, Bangalore, India

2 Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "Aldo Moro", Bari, Italy

**How to cite this article:** Hiremathad A, Piemontese L (2017) Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy. *Neural Regen Res* 12(8):1256-1261.

**Funding:** This study was supported by Intervento cofinanziato dal Fondo di Sviluppo e Coesione 2007-2013 -APQ Ricerca Regione Puglia "Programma regionale a sostegno della specializzazione intelligente e della sostenibilità sociale ed ambientale - Future In Research". Project ID: I2PCTF6 (to LP). Erasmus NAMASTE consortium (unique grant number: NAMASTE\_20140147) (to AH).

## Abstract

Nowadays, Alzheimer's disease (AD) is widely recognized as a real social problem. In fact, only five drugs are FDA approved for the therapy of this widespread neurodegenerative disease, but with low results so far. Three of them (rivastigmine, donepezil and galantamine) are acetylcholinesterase inhibitors, memantine is a N-methyl-D-aspartate receptor antagonist, whereas the fifth formulation is a combination of donepezil with memantine. The prevention and treatment of AD is the new challenge for pharmaceutical industry, as well as for public institutions, physicians, patients, and their families. The discovery of a new and safe way to cure this neurodegenerative disease is urgent and should not be delayed further. Because of the multiple origin of this pathology, a multi-target strategy is currently strongly pursued by researchers. In this review, we have discussed new structures designed to better the activity on the classical AD targets. We have also examined old and new potential drugs that could prove useful future for the therapy of the pathology by acting on innovative, not usual, and not yet fully explored targets like peroxisome proliferator-activated receptor (PPARs).

**Key Words:** Alzheimer's disease; multi-target strategy; peroxisome proliferator-activated receptors; heterocyclic compounds; neurodegenerative diseases

## Introduction

Among the neurodegenerative diseases (NDs), Alzheimer's disease (AD) is nowadays a big social problem, especially in the countries where the population's age is increasing. This awful pathology, indeed, affects the elderly population and its progression in the United States is estimated from 5 million of 2014 up to 13.8 million by 2050, excluding the development of medical innovations to prevent, slow or stop the disease (Alzheimer's Association, 2014; Hiremathad, 2017). The prevention and treatment of this neurodegenerative disease is one the most urgent challenge for pharmaceutical industry, but also for public institutions, physicians, patients, and their families (Piemontese, 2017a).

Only few drugs have been available for AD therapies over the years: just five symptomatic molecules were approved and one of them (tacrine) was recently withdrawn from the market, due to its side effects. The only non-cholinergic drug is memantine, N-methyl-D-aspartate (NMDA) receptor antagonist, that acts by restoring the A $\beta$ -induced Ca<sup>2+</sup> imbalance and is able to decrease neuronal death (Small et al., 2011; Santos et al., 2016a; Hiremathad, 2017). Donepezil, rivastigmine, and galantamine, instead, are AchE inhibitors (AchEIs) like tacrine. These molecules are able to delay the

onset of the disease for a few years and, if administered in time, can improve cognitive abilities of the patients. Therefore, it is fundamental to find new and more effective therapies, in order to decrease the high costs of public health systems and improve the quality of life of patients and their families (Piemontese, 2017a, b).

AD is widely recognized as a multifactorial disease, and this multiple origin of the pathology suggests that a key strategy for the preparation of new drugs could be found in the so-called "multi-target ligands" approach. This methodology is based on the identification of multifunctional molecules designed in order to act simultaneously on two or more targets with the aim of achieving synergistic actions and, in this way, improving the therapeutic efficacy (Santos et al., 2016a, b; Chaves et al., 2017; Piemontese, 2017a). To date, inhibition of cholinesterases (ChEIs), monoaminoxidases (MAOs) and/or beta-secretase (BACE), NMDA receptor antagonism, antioxidant activity, inhibition of beta amyloid plaques (A $\beta$ ) aggregation, and chelation of heavy metal cations (copper, iron, zinc) are among the most common investigated targets (Santos et al., 2016a, b; Piemontese, 2017a). In particular, the removal and/or redistribution of metal ions at the level of the central nervous system (CNS) can significantly reduce the formation of A $\beta$  and thus of reactive oxygen species

## \*Correspondence to:

Luca Piemontese, Ph.D.,  
luca.piemontese@uniba.it.

## orcid:

0000-0002-7980-5818  
(Luca Piemontese)  
0000-0001-7170-2614  
(Asha Hiremathad)

doi: 10.4103/1673-5374.213541

Accepted: 2017-07-14

**Table 1 Structure and related anti-AD activity of heterocyclic compounds**

Comp	Structure	R1	R2	Relevant activities
1		-	-	BACE-1=16 μM GSK-3β=7 μM
2a		3-Br	4-CH <sub>3</sub>	AChE IC <sub>50</sub> =0.117 μM
2b		3-Br	4-OCH <sub>3</sub>	BuChE IC <sub>50</sub> =0.056 μM
2c		4-OCH <sub>3</sub>	2-OH	MAO-A IC <sub>50</sub> =0.11 μM
3a		3-Br	4-Cl	AChE IC <sub>50</sub> =0.065 μM
3b		4-OCH <sub>3</sub>	4-F	MAO-A IC <sub>50</sub> =0.011 μM
3c		4-OCH <sub>3</sub>	4-Ph	BuChE IC <sub>50</sub> =0.075 μM
4		-	-	Tau Ki=13.9 nM Aβ Ki=134.2 nM
5		-	-	Tau Ki=7.9 nM Aβ Ki > 4,400 nM
6		-	-	Suppression of Aβ aggregation Antioxidant activity=1.41 fold of Trolox
7a		Y=Ph	-	AChE IC <sub>50</sub> =0.34 μM
7b		Y=PhCH <sub>2</sub>	-	Aβ inhibition=61.3%
8a		H n = 2	allyl	AChE IC <sub>50</sub> =0.30 μM
9a		H n = 3	allyl	AChE IC <sub>50</sub> =0.37 μM Aβ inhibition=78.2%
9b		H n = 3	propargyl	AChE IC <sub>50</sub> =0.35 μM Aβ inhibition=77.2%
9c		Cl n = 5	propargyl	AChE IC <sub>50</sub> =0.27 μM MAO-A IC <sub>50</sub> =77 μM MAO-B IC <sub>50</sub> =95 μM
10a		n = 2	-	AChE IC <sub>50</sub> =0.09 μM
10b		n = 3	-	AChE IC <sub>50</sub> =0.09 μM
11		-	-	Aβ inhibition=68%
12		-	-	Antioxidant EC <sub>50</sub> =147 μM
13		-	-	AChE IC <sub>50</sub> =0.50 μM
14		-	-	AChE IC <sub>50</sub> =0.092 μM BuChE IC <sub>50</sub> =0.234 μM
15		-	-	AChE IC <sub>50</sub> =0.48 μM
16		-	-	AChE IC <sub>50</sub> =0.09 μM
17a		H	-	AChE IC <sub>50</sub> =10.9 μM BuChE IC <sub>50</sub> =17.9 μM
17b		OH	-	AChE IC <sub>50</sub> =18.9 μM BuChE IC <sub>50</sub> =4.2 μM

**Table 1 Continued**

Comp	Structure	R1	R2	Relevant activities
18		-	-	AChE IC <sub>50</sub> =6.2 μM BuChE IC <sub>50</sub> =18.4 μM
19		-	-	AChE IC <sub>50</sub> = 1.0 μM BuChE IC <sub>50</sub> = 18.9 μM
20		-	-	AChE IC <sub>50</sub> = 1.1 μM BuChE IC <sub>50</sub> = 6.5 μM
21		-	-	AChE IC <sub>50</sub> = 0.016 μM BuChE IC <sub>50</sub> = 3.53 μM 5HT4R Ki = 6.6 nm
22		-	-	AChE IC <sub>50</sub> = 0.53 μM
23		-	-	AChE IC <sub>50</sub> = 0.5 μM
24		-	-	AChE IC <sub>50</sub> = 0.042 μM BuChE IC <sub>50</sub> = 1.586 μM Antioxidant EC <sub>50</sub> = 123.5 μM
25		-	-	AChE IC <sub>50</sub> = 0.57 μM BuChE IC <sub>50</sub> = 22.61 μM Antioxidant activity = 1.3 fold of Trolox
26		-	-	γ-secretase IC <sub>50</sub> (Aβ42) = 6.0 μM γ-secretase EC <sub>50</sub> (Aβ38) = 1.8 μM PPARγ EC <sub>50</sub> = 11.0 μM (Emax = 112%)

Comp: Compound; 5HT4R: 5-hydroxytryptamine 4 receptor; Aβ: β-amyloid; AChE: acetylcholinesterase; BACE-1: β-site amyloid precursor protein-cleaving enzyme 1; BuChE: butyrylcholinesterase; GSK-3β: glycogen synthase kinase-3 β; MAO-A: monoaminoxidases A; PPARγ: peroxisome proliferator-activated receptor γ; IC<sub>50</sub>: half maximal inhibitory concentration; Ki: inhibitory constant.

(ROS), which are typical of the first stages of AD (Santos et al., 2016b).

In the last two decades, many research groups have addressed their activity on the discovery of novel bioactive moieties attempting to obtain better therapeutic action and lesser side effects. Many natural and synthetic compounds became potential candidates that can protect the neurons against the degeneration. In particular, several studies were addressed to rationalize the importance of 5- and 6-terms heterocyclic rings-based compounds (reviewed by Martorana et al., 2016).

In this review, we have focused our attention on simple and complex heterocyclic structures, recently used in the design, synthesis and biological evaluation of multi-target compounds as potential new drugs for the treatment of AD. We have searched in literature for new molecules designed in order to better the activity on the classical AD targets, and for old and new potential drugs that could be useful in the future for the therapy of the pathology by acting on innovative, not usual, and not yet fully explored targets.

We selected and reviewed papers dealing on new molecules inspired by the already known structures of tacrine, donepezil and rivastigmine (two or more pharmacophoric structures that act on different targets, linked with a variable-length backbone) as well as completely different ligands that have a multi-target action, but that are designed with a different approach (single pharmacophore, active on different targets). Concerning the new possible targets for AD therapy reported in literature, we focused in the last part of the review on the peroxisome proliferator-activated receptors (PPARs). These nuclear receptors have been recently demonstrated to be involved in the process of inflammation connected with the aluminum-induced changes in media prefrontal cortex (Rafati et al., 2015). Moreover, the activation of PPARs showed *in vitro* (Pang et al., 2014) or *in vivo* (Gupta et al., 2012; Xiang et al., 2012; Barbiero et al., 2014) important improvements in the neuronal protection. Herein, we report the main results obtained studying the effect of heterocyclic compounds with PPAR activity that have shown in the recent past promising preliminary results for the treatment of AD.

### Heterocyclic Compounds as Anti-AD Agents

New heterocyclic compounds have been developed in the last years in order to find new bioactive molecules in many research fields (Piemontese et al., 2010, 2013). In particular, as far as the treatment of AD is concerned, as mentioned above, several research groups have designed and synthesized numerous ligands containing at least one heterocyclic scaffold using the multi-target approach and exploring new possible biological targets.

Prati et al. (2015) have reported on the first class of BACE-1/glycogen synthase kinase-3 beta (GSK-3 $\beta$ ) dual inhibitors based on a dihydroxy-1,3,5-triazin-2-one scaffold. Remarkably, compound **1** (Additional Table 1) showed inhibition against BACE-1 and GSK-3 $\beta$  (IC<sub>50</sub> = 16 and 7  $\mu$ M

respectively) and exhibited significant neuroprotective and neurogenic activities, with no neurotoxicity in cell based assay as well. *In vivo* pharmacokinetic studies showed good brain permeability.

Moreover, another research group (Khan et al., 2015), has demonstrated the biological activities of two series of N-heterocyclic compounds (triazolothiadiazoles and triazolothiadiazines). Fascinatingly, these molecules showed good inhibition for the acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Among all screened compounds, compound **2a** (Additional Table 1) exhibited highest inhibition with IC<sub>50</sub> = 0.117  $\pm$  0.007  $\mu$ M against AChE, while **2b** (Additional Table 1) showed strong inhibition with IC<sub>50</sub> = 0.056  $\pm$  0.001  $\mu$ M against BuChE. Another series of compounds, and in particular the molecules designed as **3a** and **3c** (Additional Table 1), showed clear selectivity over AChE and interesting IC<sub>50</sub> value (0.065  $\pm$  0.005 and 0.075  $\pm$  0.001  $\mu$ M on AChE and BuChE, respectively). Further, the same research group has tested the same molecules for their monoaminoxidases (MAO-A and MAO-B) inhibition: compounds **2c** and **3b** (Additional Table 1) resulted active against MAO-A with IC<sub>50</sub> value of 0.11  $\pm$  0.005  $\mu$ M and 0.011  $\pm$  0.001  $\mu$ M respectively, whereas, compounds **2b** (Additional Table 1) inhibited MAO-B.

Several N-pyridinyl naphthyridinamines were recently selected instead as hit compounds by Rombouts et al. (2017) after a mini-high throughput screening (HTS) on four-thousand molecules identified through 2D fragment-based similarity and 3D pharmacophoric and shape similarity. A modest selectivity was observed for compound **4** (Additional Table 1) as a potent binder to the aggregated tau *versus* A $\beta$  aggregation. Since further investigation showed that fluorination is the key point to increase the potency and selectivity, they introduced a fluoroalkyl-substitution optimizing physicochemical and kinetic properties, and obtained compound **5** (Additional Table 1), that was identified as a potent and selective tau aggregate binder with potential use as a tau PET tracer (Rombouts et al., 2017).

A further research group (Lee et al., 2014) has focused its researches on A $\beta$  aggregation, metal ion dyshomeostasis, and oxidative stress. The prototype compound **6** (Additional Table 1) showed water solubility, and brain permeability as well. The *in vitro* studies demonstrated that the ligand **6** suppresses A $\beta$  aggregation and toxicity induced by the free metal ions, and controls the formation and presence of free radical which causes the oxidative stress. Therefore, they concluded that compound **6** is a small molecule that can target and modulate several targets involved in AD.

Among the cholinesterase inhibitors, the main class of drugs available in market, tacrine (TAC) was the first molecule used in the therapy of AD. However, due to its hepatotoxicity, it was recently withdrawn from the market. Therefore, many researchers are currently making an effort to improve the drug properties through chemical modifications of the starting structure. Keri et al. (2013) have reported a series of TAC-benzothiazole (BTA) conjugates with potential

activity in AD treatment. Among all the molecules tested, compound **7a** (**Additional Table 1**) proved to be the best AChE inhibitor with  $IC_{50} = 0.34 \mu\text{M}$ , whereas compound **7b** (**Additional Table 1**) showed the highest anti- $A\beta_{42}$  self-aggregation activity (61.3%, at  $50 \mu\text{M}$ ).

In order to evaluate other AD classical targets (such as accumulation of  $A\beta$  plaques related to the oxidative damage and dyshomeostasis of redox-active biometals), in 2016 the same group has explored another set of TAC and S-allyl or propargyl cysteine hybrids (Keri et al., 2016). Using docking simulations, they have optimized the linker length for the interaction with AChE active sites. Furthermore, the compounds were explored for their *in vitro* activities for AChE and  $A\beta_{42}$  self-aggregation inhibition, as well as for their neuroprotective activity towards  $A\beta$ - and ROS-induced cellular toxicity. Remarkably, compound **8a** (**Additional Table 1**) showed the best AChE inhibition ( $IC_{50} = 0.30 \mu\text{M}$ ), though it did not show a relevant  $A\beta$  aggregation inhibition. Compound **8b** (**Additional Table 1**), on the other side, prevented the superoxide production and  $A\beta$ -induced cellular toxicity. Hiremathad et al. (2016), instead, have attempted to discover tri-hybrids compounds for AD target studies. The designed and synthesized tri-hybrids and the resulting compounds were analyzed for their biological activity as AChE inhibitors, anti-oxidants, monoaminoxidase inhibitors, and finally for their  $A\beta$ -aggregation inhibition ability. Interestingly, many compounds turn out to be more potent than TAC. In particular, chloro-substitution in position 1 increased AChE inhibition and all hybrids showed almost the same activity on the enzyme, with a range of inhibition (calculated as  $IC_{50}$ ) of  $0.27\text{--}0.37 \mu\text{M}$ . Moreover, compounds **9a** and **9b** (**Additional Table 1**) showed good  $A\beta$ -anti-aggregation ability (78.2 and 77.2 % respectively) as well. The compound with propargyl and longer linker (**9c**, **Additional Table 1**) showed the best MAO inhibitor profile. To sum up, the conjugation of three molecules improved the *in vitro* experimental results (Hiremathad et al., 2016).

Following similar goals, Quintanova et al. (2015) reported on the synthesis and the biological activity of tacrine-cinnamate and tacrine-cinnamylidene acetate conjugates as multi-target AD ligands. All synthesized hybrids showed AChE inhibition between micromolar and nanomolar range of concentrations, and among all compounds, **10a** and **10b** (**Additional Table 1**) displayed the better activity ( $IC_{50} = 0.09 \mu\text{M}$ ). Noticeably, cinnamate derivatives with hydroxyl substituents and extended allyl conjugation showed good antioxidant capacity. In addition, these compounds showed good neuroprotective effect (Quintanova et al., 2015).

With the aim to synthesize multi-target compounds with metal chelation activity, in 2013 Nunes et al. starting from the structure of 3-hydroxy-4-pyridinone (3,4-HP), a nucleus that is known to have affinity for iron and  $A\beta$  peptides, projected a new series of derivatives. In particular, they explored the conjugation of the benzothiazole (BTA) nucleus with HP instead of the TAC (as reported for compounds **9a-c**, **Additional Table 1**) and studied their capacity to inhibit AChE and antioxidant ability, as well as  $A\beta$ -self-aggregation inhibition in absence of zinc and zinc-mediated.

Their studies showed moderate AChE inhibition activity ( $IC_{50} = 14\text{--}19 \mu\text{M}$ ). Over all, this series exhibited a good  $A\beta$  anti-aggregation effect: compound **11** (**Additional Table 1**) showed the best results, with 68% inhibition and the improvement of the cell viability. Compound **12** (**Additional Table 1**), showed, on the other side, the best antioxidant capacity ( $147 \mu\text{M}$ ), and the best  $A\beta$ -self-aggregation inhibition activity in absence of zinc. Lastly, the authors evaluated the effects of selected compounds on the viability of neuronal cells stressed with  $A\beta_{42}$  protein (Keri et al., 2013).

Starting from these results, Chand et al. (2016) projected and synthesized TAC and hydroxybenzoyl-pyridone (HBP) hybrids as well, introducing the benzoyl group in the HP structure and coupled it with TAC and exploring them for their biological activities (AChE, anti-oxidant capacity) and bio-metal chelating property. Remarkably, all hybrids showed AChE inhibition in sub-micromolar range ( $IC_{50} = 0.57\text{--}0.78 \mu\text{M}$ ) and, among them, compound **13** (**Additional Table 1**) displayed the best profile ( $IC_{50} = 0.50 \pm 0.05 \mu\text{M}$ ). The radical scavenging activity was good (DPPH, 2-2 diphenyl-1-picrylhydrazyl, free radical method:  $EC_{50} = 204\text{--}249 \mu\text{M}$ ), and chelating capacity towards biometals was moderate to good ( $p\text{Fe} = 13.9$ ,  $p\text{Cu} = 6.0$  and  $p\text{Zn} = 6.0$  at pH 6.0,  $C_L/C_M = 10$ ,  $C_M = 10^{-6} \text{M}$ ).

Following a similar approach, Xie et al. (2013) reported on the design, synthesis and biological evaluation of novel TAC and coumarin hybrids. Many of these compounds inhibited ChE enzymes as well as  $A\beta$  plaques formation. Particularly, compound **14** (**Additional Table 1**) showed the highest AChE inhibition ( $IC_{50} = 0.092 \mu\text{M}$ ) and also good BuChE inhibition ( $IC_{50} = 0.234 \mu\text{M}$ ) as well as good metal chelation activity. In addition, molecular modeling studies revealed that compound **14** interacts with both central (CAS, catalytic active site), and peripheral (PAS, peripheral anionic site) sites with a mixed type AChE inhibition system.

TAC-carbazole derivatives were developed by Thirattarakul et al. (2014) instead. These molecules exhibited good AChE inhibition ( $IC_{50} = 0.48\text{--}1.03 \mu\text{M}$ ) with selectivity on BuChE and good radical scavenging capacity. In addition, they were able to reduce the neuronal death induced by oxidative stress. The ability to improve the cognitive impairments was studied by *in vivo* studies. Compound **15** (**Additional Table 1**, AChE  $IC_{50} = 0.48 \mu\text{M}$ ) was designed as the most promising molecule and it can be considered for further studies for drug development in AD (Xie et al., 2013).

The first study of hybrids that combines the steroidal alkaloid with tacrine moiety was reported by García et al. (2015). The isolation of steroidal alkaloid Solanocapsine from *S. pseudocapsicum* and its subsequent derivatization by chemical modifications were performed with the aim to modify the reactive groups in order to achieve a better AChE inhibition. A Structure-Activity Relationship (SAR) study was performed as well: the introduction of a

lipophilic group linked to the primary amine decreased inhibitory potency, whereas the effects of various substituents (with different electronic and steric characteristics) on the aromatic ring were not clearly observed. Interestingly, the authors remarked that at least one free amino group is necessary to achieve a nanomolar-range enzyme inhibition. Compound **16** (Additional Table 1) showed the most potent inhibitor activity against the AChE with  $IC_{50}$  value of 90 nM. The molecular simplification induced a significant decrease in the activity, confirming that the tetrahydroacridin moiety is crucial for the inhibition process. For this reason, this appears as an important key to develop new solanocapsine derivatives as novel pharmacophore for the AD treatment.

Other heterocyclic natural compounds inspired the design of original structures. Hydroxylated benzochromenones (urolithins), for example, were synthesized and explored for their biological activities on AD targets by Gulcan et al. (2014). Urolithins are the main bioavailable metabolites and biomarkers of ellagitannins, natural bioactive compounds that are present in various food commodities. This justifies the use of several edible plants in the folk medicine as cognitive enhancer in the treatment of AD and other kind of dementia. Unfortunately, these molecules demonstrated less potential of inhibition of AChE and BuChE. A series of benzochromenone and tetrahydro-benzochromenone, instead, showed potential activity against the same enzymes. The results of biological studies showed inhibitions comparable to the commercial drugs activity both in *in vitro* and *in vivo*. Therefore, ligands **17a**, **17b**, **18**, **19** and **20** (Additional Table 1) were indicated as lead compounds for the generation of further active molecules (Gulcan et al., 2014).

Recently, other commercial drugs have inspired the design and synthesis of novel series of multitarget-directed ligands. Starting from the structure of donepezil, C. Rochais et al. (2015) obtained several molecules that exhibited a very interesting dual binding site AChE inhibitory activity and partial serotonergic subtype-4 receptor (5-HT<sub>4</sub>R) agonist activity in nanomolar range. Among all, ligand **21** (donecopride, Additional Table 1) seems to be the most promising compound. In fact, *in vivo* studies revealed pro-cognitive, anti-amnesic effects in NMRI mice and also activity in promotion of the release of sAPP $\alpha$  in C57BL/6 mice.

Very recently, L. Monjas et al. (2017) have developed an innovative synthetic route for the preparation of several donepezil-based glutamic acid derivatives and have evaluated their pharmacological activity *in vivo* considering different AD targets. The studied compounds inhibited the AChE and protected neurons against toxic insults associated with AD. In particular, compound **22** and **23** (Additional Table 1) showed the best AChE inhibition ( $IC_{50}$  = 0.53 and 0.5  $\mu$ M respectively).

Other authors reported on their studies about a series of hybrids of donepezil and ebselen (a synthetic organoselenium drug molecule with anti-inflammatory, anti-oxidant

and cytoprotective activity, Luo et al., 2013) as multi-target ligands with anti-AD potential therapeutic use. Several compounds did not show relevant activity on the studied target, but interestingly, compound **24** (Additional Table 1) exhibited excellent AChE inhibition ( $IC_{50}$  = 0.042  $\mu$ M for electrophorus electricus AChE) and strong BuChE inhibition ( $IC_{50}$  = 1.586  $\mu$ M). In addition, these molecules exhibited good radical scavenging capacity (123.5  $\mu$ M) and did not show acute toxicity in mice at doses of up to 2000 mg/kg. Moreover, compound **24** seems to be relatively able to penetrate the central nervous system (Luo et al., 2013).

New scutellarin-rivastigmine hybrids were designed and synthesized by Sang et al. (2015) instead. The biological evaluation revealed that these compounds are good AChE and BuChE inhibitors, with neuroprotective and antioxidant effects and good capacity of biometal chelation. Additionally, the *in vivo* studies indicated good neuroprotective effects in scopolamine-induced cognitive impairment. Compound **25** (Additional Table 1) showed the most promising enzymatic activity ( $IC_{50}$  = 0.57 and 22.61  $\mu$ M, for AChE and BuChE, respectively) and a promising anti-oxidant activity (1.3 fold of Trolox, used as a reference compound). The *in vitro* studies suggested that **25** could cross the blood-brain barrier as well (Sang et al., 2015).

### Heterocyclic Compounds as PPAR Agonists: a New Target for AD Therapy

Recently, new targets for the treatment of neurodegenerative diseases were explored, starting from a new consideration of further studies performed on several drugs already used in therapy. In particular, PPAR agonists seem to be very promising new agents for the treatment of AD.

The classical drugs that act through PPARs activation are fibrates and glitazones. These molecules were used over the years in the therapies of atherosclerosis and diabetes. Many efforts have been made in the last 20 years with the aim of obtaining a single ligand able of acting on hyperlipidemia and type 2 diabetes (Fracchiolla et al., 2008, 2012; Carrieri et al., 2013; Laghezza et al., 2015; Piemontese et al., 2015, 2017c), in order to better the compliance of the patients. In fact, these diseases are very often associated (in a condition defined as metabolic syndrome), and the treatment of both pathologies with one drug only was for many years a goal for pharmaceutical industry. Fascinatingly, PPAR ligands, if well projected, seem to be useful in the treatment of NDs as well (Piemontese et al., 2017a).

In a recent study, Cheng et al. (2015) determined the effects of PPAR $\alpha$  activation on neuronal degeneration by using a model of A $\beta_{42}$ -induced cytotoxicity. They concluded that the mitochondrial-associated AIF/Endo G-dependent pathway can be hindered by activation of receptor in the model. Therefore, they suggest that PPAR $\alpha$  activation should be considered as an innovative potential strategy for the treatment of AD.

PPAR $\gamma$  activation was demonstrated, on the other side, to influence the amyloid- $\beta$  precursor protein (APP) cleavage

by suppressing the transcription of APP processing enzyme BACE-1, thus leading to decreased A $\beta$  levels. Moreover, PPAR $\gamma$  agonists are able to enhance the degradation of A $\beta$  by microglia (Yamanaka et al., 2012) and inhibit pro-inflammatory gene expression (Jiang et al., 1998; Ricote et al., 1998).

In particular, the ligand **26 (Additional Table 1)** presented a promising *in vitro* activity ( $\gamma$ -secretase: IC<sub>50</sub> (A $\beta$ <sub>42</sub>) = 6.0  $\mu$ M; EC<sub>50</sub> (A $\beta$ <sub>38</sub>) = 1.8  $\mu$ M and PPAR $\gamma$ : EC<sub>50</sub> = 11.0  $\mu$ M, maximum activation: 112%) (Hieke et al., 2010). The pharmacokinetic properties of this molecule were recently studied in order to address further preclinical pharmacodynamic animal studies (Pellowska et al., 2015).

Recently, the anti-diabetic approved drug pioglitazone (PPAR $\gamma$  full agonist) was subjected to clinical studies in order to deepen the possibility of its use for the treatment of AD. The aims of this investigation in Phase II trial, planned as co-administration of the drug with an AChE inhibitor and memantine in patients with mild to moderate AD, were safety and tolerability, and therefore no significant results on cognitive measures were shown. Pioglitazone was well tolerated, with few side effects. This study will permit to calculate the population to be treated in Phase III (Galimberti et al., 2016). Obviously, further studies will clarify the possibility of the use of pioglitazone in the therapeutic protocols for AD.

## Conclusion

The use of AChE inhibitors or NMDA receptor antagonist drugs, joint with a correct diet and with the consumption of selected food supplements with antioxidant properties (Piemontese, 2017a, b) is actually the only weapon able to prevent and treat AD in the early stage of pathology.

However, the discovery of a new, safe, selective way to treat AD could provide a breakthrough for physicians, patients and pharmaceutical industry. Along this direction, heterocyclic scaffolds were widely used in the synthesis of new potential drugs over the last twenty years with promising but still partial results.

The identification of molecules with interesting multi-target profile, the screening of old drugs that are proved effective through the interaction with new important targets and the preparation of natural-based synthetic molecules might be the key to finally achieve this fundamental goal and restore hope for Earth's population.

**Author contributions:** AH and LP wrote the first draft of the paper. LP coordinated the work and revised the final draft of the paper.

**Conflicts of interest:** None declared.

**Plagiarism check:** Checked twice by iThenticate.

**Peer review:** Externally peer reviewed.

**Open access statement:** This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

**Open peer reviewer:** Willian Orlando Castillo, Universidade de Sao Paulo, Brazil.

**Additional file:** Additional Table 1 Structure and related anti-AD activity of heterocyclic compounds.

## References

- Alzheimer's Association (2014) Alzheimer's disease facts and figures. *Alzheimers Dement* 10:47-92.
- Barbiero JK, Santiago RM, Persike DS, da Silva Fernandes MJ, Tonin FS, da Cunha C, Lucio Boschen S, Lima MM, Vital MA (2014) Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *Behav Brain Res* 274:390-399.
- Carrieri A, Giudici M, Parente M, De Rosas M, Piemontese L, Fracchiolla G, Laghezza A, Tortorella P, Carbonara G, Lavecchia A, Gilardi F, Crestani M, Liodice F (2013) Molecular determinants for nuclear receptors selectivity: Chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors  $\alpha/\gamma$  agonists. *Eur J Med Chem* 63:321-332.
- Chand K, Alsoghier HM, Chaves S, Santos MA (2016) Tacrine-(hydroxybenzoyl-pyridone) hybrids as potential multifunctional anti-Alzheimer's agents: AChE inhibition, antioxidant activity and metal chelating capacity. *J Inorg Biochem* 163:266-277.
- Chaves S, Piemontese L, Hiremathad A, Santos MA (2017) Hydroxypyridinone derivatives: a fascinating class of chelators with therapeutic applications - an update. *Curr Med Chem* doi: 10.2174/0929867324666170330092304.
- Cheng YH, Lai SW, Chen PY, Chang JH, Chang NW (2015) PPAR $\alpha$  activation attenuates amyloid- $\beta$ -dependent neurodegeneration by modulating endo G and AIF translocation. *Neurotox Res* 27:55-68.
- Fracchiolla G, Lavecchia A, Laghezza A, Piemontese L, Trisolini R, Carbonara G, Tortorella P, Novellino E and Liodice F (2008) Synthesis, biological evaluation and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPAR $\alpha$  and PPAR $\gamma$  agonist activity. *Bioorg Med Chem* 16:9498-9510.
- Fracchiolla G, Laghezza A, Piemontese L, Parente M, Lavecchia A, Pochetti G, Montanari R, Di Giovanni C, Carbonara G, Tortorella P, Novellino E and Liodice F (2012) Synthesis, biological evaluation and molecular investigation of fluorinated PPAR $\alpha$ /gamma dual agonists. *Bioorg Med Chem* 20:2141-2151.
- Galimberti D, Scarpini E (2016) Pioglitazone for the treatment of Alzheimer's disease. *Expert Opin Investig Drugs* doi: 10.1080/13543784.2017.1265504.
- García ME, Borioni JL, Cavallaro V, Puiatti M, Pierini AB, Murray AP, Peñéñory AB (2015) Solanocapsine derivatives as potential inhibitors of acetylcholinesterase: synthesis, molecular docking and biological studies. *Steroids* 104:95-110.
- Gulcan HO, Unlu S, Esiringu I, Ercetin T, Sahin Y, Oz D, Sahin MF (2014) Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors. *Bioorg Med Chem* 22:5141-5154.
- Gupta R, Gupta LK (2012) Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease. *Pharm Biochem Behav* 102:184-190.
- Hieke M, Ness J, Steri R, Dittrich M, Greiner C, Werz O, Baumann K, Schubert-Zsilavecz M, Weggen S, Zettl H (2010) Design, synthesis, and biological evaluation of a novel class of  $\gamma$ -secretase modulators with PPAR activity. *J Med Chem* 53:4691-4700.
- Hiremathad A, Chand K, Esteves AR, Cardoso SM, Ramsay RR, Chaves S, Keri RS, Santos MA (2016) Tacrine-allyl/propargylcysteine-benzothiazole trihybrids as potential anti-Alzheimer's drug candidates. *RSC Adv* 6:53519-53532.
- Hiremathad A (2017) A review: Natural compounds as anti-Alzheimer's disease agents. *Curr Food Nutr Sci* doi:10.2174/1573401313666170725103932.
- Keri RS, Quintanova C, Marques SM, Esteves AR, Cardoso SM, Santos MA (2013) Design, synthesis and neuroprotective evaluation of novel tacrine-benzothiazole hybrids as multi-targeted compounds against Alzheimer's disease. *Bioorg Med Chem* 21:4559-4569.
- Keri RS, Quintanova C, Chaves S, Silva DF, Cardoso SM, Santos MA (2016) New tacrine hybrids with natural-based cysteine derivatives as multitargeted drugs for potential treatment of Alzheimer's disease. *Chem Biol Drug Des* 8:101-111.

- Khan I, Bakht SM, Ibrar A, Abbas S, Hameed S, White JM, Rana UA, Zaib S, Shahid M, Iqbal J (2015) Exploration of a library of triazolothiadiazole and triazolothiadiazine compounds as a highly potent and selective family of cholinesterase and monoamine oxidase inhibitors: design, synthesis, X-ray diffraction analysis and molecular docking studies. *RSC Adv* 5:21249-21267.
- Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of mono-cyte inflammatory cytokines. *Nature* 391:82-86.
- Laghezza A, Montanari R, Lavecchia A, Piemontese L, Pochetti G, Iacobazzi V, Infantino V, Capelli D, De Bellis M, Liantonio A, Pierno S, Tortorella P, Conte Camerino D, Loiodice F (2015) On the metabolically active form of metaglidase: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles. *Chem Med Chem* 10:555-565.
- Lee S, Zheng X, Krishnamoorthy J, Savelieff MG, Park HM, Brender JR, Kim JH, Derrick JS, Kochi A, Lee HJ, Kim C, Ramamoorthy A, Bowers MT, Lim MH (2014) Rational design of a structural framework with potential use to develop chemical reagents that target and modulate multiple facets of Alzheimer's disease. *J Am Chem Soc* 136:299-310.
- Luo Z, Sheng J, Sun Y, Lu C, Yan J, Liu A, Luo HB, Huang L, Li X (2013) Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen. *J Med Chem* 56:9089-9099.
- Martorana A, Giacalone V, Bonsignore R, Pace A, Gentile C, Pibiri I, Buscemi S, Lauria A, Piccionello AP (2016) Heterocyclic scaffolds for the treatment of Alzheimer's disease. *Curr Pharm Des* 22:3971-3995.
- Monjas L, Arce MP, León R, Egea J, Pérez C, Villarroya M, López MG, Gil C, Conde S, Isabel Rodríguez-Franco M (2017) Enzymatic and solid-phase synthesis of new donepezil-based L- and D-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. *Eur J Med Chem* 13:60-72.
- Nunes A, Marques SM, Quintanova C, Silva DF, Cardoso SM, Chaves S, Santos MA (2013) Multifunctional iron-chelators with protective roles against neurodegenerative diseases. *Dalton Trans* 42:6058-6073.
- Pang T, Sun LX, Wang T, Jiang ZZ, Liao H, Zhang LJ (2014) Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPAR $\gamma$  and the Akt/GSK-3 $\beta$  pathway. *Acta Pharm Sinica* 35:727-737.
- Pellowiska M, Stein C, Pohland M, Merk D, Klein J, Eckert GP, Schubert-Zsilavec M, Wurglics M (2015) Pharmacokinetic properties of MH84, a  $\gamma$ -secretase modulator with PPAR $\gamma$  agonistic activity. *J Pharm Biomed Anal* 102:417-424.
- Piemontese L, Carbonara G, Fracchiolla G, Laghezza A, Tortorella P, Loiodice F (2010) Convenient synthesis of some 3-phenyl-1-benzofuran-2-carboxylic acid derivatives as new potential inhibitors of ClC-Kb channels. *Heterocycles* 12:2865-2872.
- Piemontese L, Laghezza A, Fracchiolla G, Carbonara G, Tortorella P, Loiodice F (2013) An efficient synthesis of the optically active isomers of 2H-1,4-benzoxazine derivatives, novel KATP channel modulators. *Tetr Asy* 24:791-795.
- Piemontese L, Fracchiolla G, Carrieri A, Parente M, Laghezza A, Carbonara G, Sblano S, Tauro M, Gilardi F, Tortorella P, Lavecchia A, Crestani M, Desvergne B, Loiodice F (2015) Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor  $\alpha/\gamma$  ligand LT175. *Eur J Med Chem* 90:583-594.
- Piemontese L (2017a) New approaches for prevention and treatment of Alzheimer's disease: a fascinating challenge. *Neural Regen Res* 12:405-406.
- Piemontese L (2017b) Plant food supplements with antioxidant properties for the treatment of chronic and neurodegenerative diseases: benefits or risks? *J Diet Suppl* 14:478-484.
- Piemontese L, Cerchia C, Laghezza A, Ziccardi P, Sblano S, Tortorella P, Iacobazzi V, Infantino V, Convertini P, Dal Piaz F, Lupo A, Colantuoni V, Lavecchia A, Loiodice F (2017c) New diphenylmethane derivatives as peroxisome proliferator-activated receptor  $\alpha/\gamma$  dual agonists endowed with anti-proliferative effects and mitochondrial activity. *Eur J Med Chem* 127:379-397.
- Prati F, De Simone A, Armirotti A, Summa M, Pizzirani D, Scarpelli R, Mandrup Bertozzi S, Perez DI, Andrisano V, Perez-Castillo A, Monti B, Massenzio F, Polito L, Racchi M, Sabatino P, Bottegoni G, Martinez A, Cavalli A, Bolognesi ML (2015) 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the first dual BACE-1/GSK-3 $\beta$  fragment hits against Alzheimer's disease. *ACS Chem Neurosci* 6:1665-1682.
- Quintanova C, Keri RS, Marques SM, Fernandes MG, Cardoso SM, Serralheiro ML, Santos MA (2015) Design, synthesis and bioevaluation of tacrine hybrids with cinnamate and cinnamylidene acetate derivatives as potential anti-Alzheimer drugs. *Med Chem Comm* 6:1969-1977.
- Rafati A, Yazdani H, Noorafshan A (2015) Pioglitazone ameliorates neuron loss in the cortex after aluminum-treatment in rats. *Neurol Res Int* 2015:381934.
- Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. *Nature* 391:79-82.
- Rochais C, Lecoutey C, Gaven F, Giannoni P, Hamidouche K, Hedou D, Dubost E, Genest D, Yahiaoui S, Freret T, Bouet V, Dauphin F, Sopkova de Oliveira Santos J, Ballandonne C, Corvaisier S, Malzert-Fréon A, Legay R, Boulouard M, Claeysen S, Dallemagne P (2015) Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT $4$ R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. *J Med Chem* 58:3172-3187.
- Rombouts FJR, Andrés J-I, Ariza M, Alonso JM, Austin N, Bittelbergs A, Chen L, Chupakhin V, Cleiren E, Fierens K, Fontana A, Langlois X, Leenaerts JE, Mariën J, Martinez Lamencas C, Salter R, Schmidt ME, Te Riele P, Wintmolders C, Trabanco AA, Zhang W, Macdonald GJ, Moechars D (2017) Discovery of N-(Pyridin-4-yl)-1,5-naphthyridin-2-amine as potential tau pathology PET tracers for Alzheimer's disease. *J Med Chem* 60:1272-1291.
- Sang Z, Li Y, Qiang X, Xiao G, Liu Q, Tan Z, Deng Y (2015) Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease. *Bioorg Med Chem* 23:668-680.
- Santos MA, Chand K, Chaves S (2016a) Recent progress in multifunctional metal chelators as potential drugs for Alzheimer's disease. *Cord Chem Rev* 327-328:287-303.
- Santos MA, Chand K, Chaves S (2016b) Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy. *Future Med Chem* 8:2113-2142.
- Small G, Bullock R (2011) Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease. *Alzheimers Dement* 7:177-184.
- Thirratmatrakul S, Yenjai C, Waiwut P, Vajragupta O, Reubroycharoen P, Tohda M, Boonyarat C (2014) Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease. *Eur J Med Chem* 75:21-30.
- Xiang GQ, Tang SS, Jiang LJ, Hong H, Li Q, Wang C, Wang XY, Zhang TT, Yin L (2012) PPAR $\gamma$  agonist pioglitazone improves scopolamine-induced memory impairment in mice. *J Pharm Pharmacol* 64:589-596.
- Xie SS, Wang XB, Li JY, Yang L, Kong LY (2013) Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease. *Eur J Med Chem* 64:540-553.
- Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT (2012) PPAR/RXR-induced and CD36-mediated microglial amyloid phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin mice. *J Neurosci* 32:17321-17331.